GlaxoSmithKline Plc (GSK):企業の財務及び戦略的SWOT分析

GlobalDataが発行した調査報告書(GDPH4279FSA)
◆英語タイトル:GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH4279FSA
◆発行会社(リサーチ会社):GlobalData
◆発行日:2016年2月16日
◆ページ数:111
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD125 ⇒換算¥13,625見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD375 ⇒換算¥40,875見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

GlaxoSmithKline Plc (GSK) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

GlaxoSmithKline plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of respiratory, cardiovascular, metabolic and urological diseases, immuno-inflammation and cancer, among others. The company offers over-the-counter products for pain relief, oral health, nutrition, skin health and gastrointestinal disorders. Its vaccine portfolio cover various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company operates research facilities in France, Germany, the UK, Belgium, Spain, the US, Canada, and China. Its operations span Asia and the Middle East, Australasia, North America, South and Central America, and Europe. GSK is headquartered in Middlesex, the UK.

GlaxoSmithKline Plc Key Recent Developments

Feb 11, 2016: GSK responds to latest report from the O’Neill Review on antibiotic resistance
Feb 03, 2016: GSK Announces Full year and Fourth Quarter 2015 Results
Jan 25, 2016: AstraZeneca partners with peers and academia to establish translational research fund
Jan 20, 2016: Scientists Indicted For Allegedly Stealing Biopharmaceutical Trade Secrets
Dec 22, 2015: Mimetas and Partners Receive 1.6 Million Dollar Industry Funding for Development of Organ-On-A-Chip Neurotoxicity Models

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 – About the Company 6
GlaxoSmithKline Plc – Key Facts 6
GlaxoSmithKline Plc – Key Employees 7
GlaxoSmithKline Plc – Key Employee Biographies 8
GlaxoSmithKline Plc – Major Products and Services 9
GlaxoSmithKline Plc – Pharmaceutical Pipeline Products Data 11
GlaxoSmithKline Plc, Pipeline Products by Therapy Area 11
GlaxoSmithKline Plc, Pipeline Products by Development Phase 12
GlaxoSmithKline Plc – Medical Equipment Pipeline Products Data 25
GlaxoSmithKline Plc Pipeline Products by Equipment Type 25
GlaxoSmithKline Plc – History 27
GlaxoSmithKline Plc – Company Statement 53
GlaxoSmithKline Plc – Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
GlaxoSmithKline Plc – Key Manufacturing Facilities 67
Joint Venture 67
Section 2 – Company Analysis 68
GlaxoSmithKline Plc – Business Description 68
GlaxoSmithKline Plc – Corporate Strategy 69
GlaxoSmithKline Plc – SWOT Analysis 70
SWOT Analysis – Overview 70
GlaxoSmithKline Plc – Strengths 70
Strength – Leading Product Categories 70
Strength – Focused Research and Development Capabilities 70
Strength – Leading Market Position 70
GlaxoSmithKline Plc – Weaknesses 71
Weakness – False Advertisements and Law Violations 71
Weakness – Product Defects 71
Weakness – Generic Competition Hits Established Products 71
GlaxoSmithKline Plc – Opportunities 72
Opportunity – New Product Approvals and Launches 72
Opportunity – Late Stage Pipeline Products 72
Opportunity – Business Initiatives 72
GlaxoSmithKline Plc – Threats 73
Threat – Uncertain R&D Outcomes 73
Threat – Government Regulations 73
Threat – Competitive Pressures 73
GlaxoSmithKline Plc – Key Competitors 74
Section 3 – Company Financial Ratios 75
Financial Ratios – Capital Market Ratios 75
Financial Ratios – Annual Ratios 76
Performance Chart 78
Financial Performance 78
Financial Ratios – Interim Ratios 79
Financial Ratios – Ratio Charts 80
Section 4 – Company’s Lifesciences, Power Financial Deals and Alliances 81
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 81
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 82
GlaxoSmithKline Plc, Medical Equipment, Deals By Year, 2010 to YTD 2016 83
GlaxoSmithKline Plc, Medical Equipment, Deals By Type, 2010 to YTD 2016 84
GlaxoSmithKline Plc, Recent Deals Summary 85
Section 5 – Company’s Recent Developments 87
Feb 11, 2016: GSK responds to latest report from the O’Neill Review on antibiotic resistance 87
Feb 03, 2016: GSK Announces Full year and Fourth Quarter 2015 Results 88
Jan 25, 2016: AstraZeneca partners with peers and academia to establish translational research fund 90
Jan 20, 2016: Scientists Indicted For Allegedly Stealing Biopharmaceutical Trade Secrets 91
Dec 22, 2015: Mimetas and Partners Receive 1.6 Million Dollar Industry Funding for Development of Organ-On-A-Chip Neurotoxicity Models 92
Dec 21, 2015: ICER Draft Reports on Nucala (Mepolizumab) for Asthma and Tresiba (Insulin Degludec) for Diabetes Posted for Public Comment 93
Dec 15, 2015: Comic Relief and GSK form five-year partnership to fight malaria and strengthen health systems 95
Dec 07, 2015: GSK Selects Accenture’s Life Sciences Cloud for R&D to Simplify and Speed its Drug Development Process 97
Nov 12, 2015: MSF launches global action against Pfizer and GlaxoSmithKline to cut the price of the pneumonia vaccine 98
Oct 28, 2015: GSK: Results for third quarter 2015 99
Section 6 – Appendix 107
Methodology 107
Ratio Definitions 107
About GlobalData 111
Contact Us 111
Disclaimer 111

List of Tables
GlaxoSmithKline Plc, Key Facts 6
GlaxoSmithKline Plc, Key Employees 7
GlaxoSmithKline Plc, Key Employee Biographies 8
GlaxoSmithKline Plc, Major Products and Services 9
GlaxoSmithKline Plc, Number of Pipeline Products by Therapy Area 11
GlaxoSmithKline Plc, Number of Pipeline Products by Development Stage 12
GlaxoSmithKline Plc, Pipeline Products By Therapy Area and Development Phase 13
GlaxoSmithKline Plc Number of Pipeline Products by Equipment Type 25
GlaxoSmithKline Plc Pipeline Products by Equipment Type 26
GlaxoSmithKline Plc, History 27
GlaxoSmithKline Plc, Other Locations 55
GlaxoSmithKline Plc, Subsidiaries 55
GlaxoSmithKline Plc, Key Manufacturing Facilities 67
GlaxoSmithKline Plc, Joint Venture 67
GlaxoSmithKline Plc, Key Competitors 74
GlaxoSmithKline Plc, Ratios based on current share price 75
GlaxoSmithKline Plc, Annual Ratios 76
GlaxoSmithKline Plc, Interim Ratios 79
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 81
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 82
GlaxoSmithKline Plc, Medical Equipment, Deals By Year, 2010 to YTD 2016 83
GlaxoSmithKline Plc, Medical Equipment, Deals By Type, 2010 to YTD 2016 84
GlaxoSmithKline Plc, Recent Deals Summary 85
Currency Codes 107
Capital Market Ratios 107
Equity Ratios 108
Profitability Ratios 108
Cost Ratios 109
Liquidity Ratios 109
Leverage Ratios 110
Efficiency Ratios 110

List of Figures
GlaxoSmithKline Plc, Pipeline Products by Therapy Area 11
GlaxoSmithKline Plc, Pipeline Products by Development Phase 12
GlaxoSmithKline Plc Pipeline Products by Equipment Type 25
GlaxoSmithKline Plc, Performance Chart (2011 - 2015) 78
GlaxoSmithKline Plc, Ratio Charts 80
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 81
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 82
GlaxoSmithKline Plc, Medical Equipment, Deals By Year, 2010 to YTD 2016 83
GlaxoSmithKline Plc, Medical Equipment, Deals by Type, 2010 to YTD 2016 84

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ GlaxoSmithKline Plc (GSK):企業の財務及び戦略的SWOT分析(GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆